Home > Healthcare > Biotechnology > Biotechnology R&D > DNA Microarray Market

DNA Microarray Market Trends

Report ID: GMI6689
Published Date: Sep 2023
Report Format: PDF

Download Free Sample

DNA Microarray Market Trends

The growing prevalence of genetic disorders and cancers has emerged as a significant driver, propelling the expansion of the market. For instance, according to the World Health Organization (WHO), genetic disorders and congenital abnormalities occur in about 2%-5% of all live births, account for up to 30% of paediatric hospital admissions and cause about 50% of childhood deaths in industrialized countries. Similarly, as per American Cancer Society report, in 2022, there was an estimated 1.9 million new cancer cases diagnosed and 609,360 cancer deaths in the U.S. Thus, rising cases of genetic disorders and cancers necessitate comprehensive genetic profiling and diagnostics for accurate disease identification.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

DNA microarray industry size was USD 3.4 billion in 2022 and will register 8.7% CAGR from 2023-2032 due to rising adoption in scientific and medical applications along with the ongoing advancements in genomics worldwide.

The consumables product segment recorded 46.7% revenue share of the market in 2022 on account of the rising shift towards precision medicine and pharmacogenomics in the industry.

North America registered 42.1% share of the DNA microarray industry in 2022 and is expected to register appreciable growth from 2023-2032 owing to the growing investments in cutting-edge research and development initiatives in the region.

Thermo Fisher Scientific, Inc, QIAGEN, Illumina, Inc., Agilent Technologies, Inc., Merck & Co., Inc., and bioMérieux SA are some of the major DNA microarray companies worldwide.